載入...
Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is more effective than its predecessor bicalutamide, which was analyzed in head-to-head studies of patients with CRPC. This family...
Na minha lista:
| 發表在: | Res Rep Urol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5818862/ https://ncbi.nlm.nih.gov/pubmed/29497605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/RRU.S157116 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|